|
JEWEL
Ongoing trial
 |
Author(s) |
Hobbs FDR, Gensini G, Mancini GBJ, Manolis AJ, Bauer B, Böhler S, Genest J, Feldman R, Harvey P, Jenssen TG, Metcalfe M, Marques da Silva P
|
 |
Title(s) |
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The Jewel Program) |
|
Reference(s) |
Int J Cardiol 2006;110:242–50 |
|
Disease |
Hypertension, hypercholesterolaemia |
|
Purpose |
To assess the effectiveness of a single pill containing amlodipine and atorvastatin in helping patients achieve BP and LDL-cholesterol targets as defined by local guidelines |
|
Study design |
Open |
|
Follow-up |
Aim 16 weeks
|
|
Patients |
Aim 2850 patients (at least 1250 JEWEL I, at least 1300 JEWEL II), aged 18–80 years, with hypertension and elevated LDL cholesterol, both treated or untreated |
|
Treatment regimen |
Single-pill amlodipine and atorvastatin, 5/10 mg/day, titrated to 10/80 mg/day, at the discretion of the physician |
|
Results |
Not yet available |
|
|
|
